An in-depth look at Ultimovacs’ cancer vaccine
The field of immuno-oncology is growing, and cancer vaccines are a big part of that. Norwegian biotech Ultimovacs is developing its own cancer vaccine technology platform. BioStock invited Sara Mangsbo, Chief Innovation Officer at Ultimovacs, to the Studio to learn more.
Watch the interview with Ultimovacs‘ CIO Sara Mangsbo below.
Read BioStock’s overview of cancer vaccines here.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
